Is Camzyos affected by genetics?

Yes — the active ingredient is metabolized by a gene known to vary between individuals.

Relevant genes: CYP2C19

Camzyos is affected by pharmacogenetics through the CYP2C19 gene. Your genotype for this gene can change how your body processes Camzyos, which can affect both how well it works and how well you tolerate it. The strongest evidence level on this page is Strong, based on CPIC or FDA guidelines.

What's in Camzyos

mavacamten affected by CYP2C19

Affected by CYP2C19 · FDA · Strong evidence

Read the full mavacamten genetics guide →

Mavacamten phenotype recommendations

Published guidance from FDA on how mavacamten should be dosed or substituted based on your CYP2C19 phenotype.

Phenotype	What it means	Recommendation	Evidence
Ultrarapid Metabolizer CYP2C19	Your body processes mavacamten at a normal rate. The standard dose should work as expected.	FDA Initiate therapy with recommended starting dose.	—
Rapid Metabolizer CYP2C19	Your body processes mavacamten at a normal rate. The standard dose should work as expected.	FDA Initiate therapy with recommended starting dose.	—
Normal Metabolizer CYP2C19	Your body processes mavacamten at a normal rate. The standard dose should work as expected.	FDA Initiate therapy with recommended starting dose.	Strong
Intermediate Metabolizer CYP2C19	Your body breaks down mavacamten slightly slower than normal, which may lead to higher drug levels. Your doctor will monitor you closely and adjust the dose based on your response.	FDA Follow FDA labeling dose titration and monitoring schedule. Monitor closely for signs of heart failure due to higher systemic concentrations.	Moderate
Poor Metabolizer CYP2C19	Your body breaks down mavacamten much more slowly than normal, causing higher drug levels that may increase the risk of heart failure. Your doctor will monitor you closely and adjust the dose based on your response.	FDA Follow FDA labeling dose titration and monitoring schedule. Monitor closely for signs of heart failure. Use caution due to significantly higher systemic concentrations.	Strong
Likely Intermediate Metabolizer CYP2C19	Your body likely breaks down mavacamten slightly slower than normal, which may lead to higher drug levels. Your doctor will monitor you closely and adjust the dose based on your response.	FDA Follow FDA labeling dose titration and monitoring schedule. Monitor closely for signs of heart failure due to higher systemic concentrations.	Moderate
Likely Poor Metabolizer CYP2C19	Your body likely breaks down mavacamten much more slowly than normal, causing higher drug levels that may increase the risk of heart failure. Your doctor will monitor you closely and adjust the dose based on your response.	FDA Follow FDA labeling dose titration and monitoring schedule. Monitor closely for signs of heart failure. Use caution due to significantly higher systemic concentrations.	Strong
Indeterminate CYP2C19	Your genetic test result does not give a clear answer on how your body processes mavacamten.	FDA Initiate therapy with recommended starting dose.	—
Not available CYP2C19	Your genetic test result does not give a clear answer on how your body processes mavacamten.	FDA Initiate therapy with recommended starting dose.	—

Source: FDA

The gene behind the guidance

CYP2C19 Cytochrome P450 2C19

CYP2C19 handles several SSRIs (citalopram, escitalopram, sertraline), proton pump inhibitors (omeprazole, esomeprazole), and the blood thinner clopidogrel. About 2 to 5 percent of people of European descent and 15 to 20 percent of people of East Asian descent are poor metabolizers. Another 30 percent carry a rapid-metabolizer variant.

Rapid metabolizers clear affected drugs before they reach therapeutic levels. Poor metabolizers accumulate the drug and feel stronger effects.

See all drugs affected by CYP2C19 →

Related medications

Find out how your genetics affect Camzyos

This page describes the general pharmacogenetics. A Gene2Rx report analyzes your own DNA to tell you which metabolizer group you fall into, across every medication.

Get your report Look up another medication

Informational only — not medical advice. Pharmacogenetic guidance describes population-level patterns; your individual response depends on many factors. Never start, stop, or change a medication without talking to your prescribing clinician.